Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research6/19/2026Positive
IMVT
Immunovant IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.23B
P/E Ratio
—
EPS
$-2.88
Beta
0.77
52W High
$40.77
52W Low
$14.32
50-Day MA
$32.39
200-Day MA
$25.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-532.49M |
| Operating Margin | 0.00% |
| Return on Equity | -64.80% |
| Return on Assets | -38.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.18 |
| Price-to-Book | 9.34 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -14.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $205.31M |
| Float | $78.75M |
| % Insiders | 56.60% |
| % Institutions | 54.68% |
Historical Volatility
HV 10-Day
23.54%
HV 20-Day
36.86%
HV 30-Day
43.66%
HV 60-Day
77.47%
HV Rank
12.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($46.00 target)
2
Strong Buy11
Buy5
HoldLatest News
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Zacks Investment Research6/12/2026Positive
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.
Seeking Alpha5/25/2026Positive
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.
Seeking Alpha5/21/2026Positive
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
Zacks Investment Research5/21/2026Positive
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
Immunovant reports clinically meaningful trial results for its lead drug candidate. That's good news for Roivant Sciences.
Barrons5/20/2026Positive
Immunovant Q4 Earnings Call Highlights
Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.
MarketBeat5/20/2026Neutral
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026.
GlobeNewsWire5/20/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026